As of March, 14 Analysts See $0.84 EPS for Harrow Health, Inc. (HROW)

Harrow Health, Inc. (NASDAQ:HROW)’s earnings release is expected by WallStreet on March, 14, RTT reports. Analysts expect change of 746.15 % or $0.97 from previous year’s $-0.13 EPS compared to current’s $0.84 EPS. HROW’s profit could hit $19.55M if the current EPS of $0.84 is accurate. Wall Street now forecasts -800.00 % EPS growth despite Harrow Health, Inc. previous quarter’s EPS of $-0.12. HROW is touching $6.86 during the last trading session, after decreased 1.15%.Harrow Health, Inc. has volume of 139,439 shares. Since March 3, 2018 HROW has 0.00% and is . The stock the S&P500 by 0.00%.

Harrow Health, Inc. owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States.The firm is valued at $159.69 million. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.Last it reported negative earnings. The firm also develops and commercializes therapeutics for the ocular surface diseases.

For more Harrow Health, Inc. (NASDAQ:HROW) news released briefly go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Investingnews.com. The titles are as follows: “Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc. – Nasdaq” released on December 31, 2018, “U.S. Global Investors’ (GROW) CEO Frank Holmes on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” on February 14, 2019, “Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary – Nasdaq” with a publish date: February 05, 2019, “Harrow Health to Announce Fourth Quarter 2018 Financial Results on March 12, 2019 – Nasdaq” and the last “GoldSpot Goes Public and Starts Trading on the TSXV – Investing News Network” with publication date: February 21, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.